论文部分内容阅读
用免疫组化法检测了５５例乳腺癌和１３例乳腺良性病变的增殖细胞核抗原（ＰＣＮＡ）。结果ＰＣＮＡ增殖指数在乳腺用为０％～８１％（中位数２０％），在乳腺良性病变为０％～６８％（中位数５％），乳腺癌中高于乳腺良性病变（Ｐ＜０．００２）．在乳腺癌中ＰＣＮＡ表达与组织学分级（Ｐ＜０．００１）、淋巴结转移（Ｐ＜０．０１）及组织蛋白酶Ｄ（ＣａｔｈＤ）间质表达（Ｐ＜０．０２５）呈正相关，与ＣａｔｈＤ实质表达（Ｐ＜０．０２５）、无病生存期（Ｐ＜０．０２５）及总生存期（Ｐ＜０．０５）呈负相关。提示ＰＣＮＡ能反映细胞的增殖状态，其高表达可预测复发率高和生存期短，检测ＰＣＮＡ对乳腺癌的辅助治疗可能有帮助。
Using immunohistochemistry, proliferating cell nuclear antigen (PCNA) was detected in 55 cases of breast cancer and 13 cases of benign breast lesions. Results The PCNA proliferation index was 0% to 81% (median 20%) in the breast, and 0% to 68% (median 5%) in the benign breast lesions. Breast cancer was higher than benign breast lesions (P<0. .002). PCNA expression was positively correlated with histological grading (P<0.001), lymph node metastasis (P<0.01), and cathepsin D (CathD) interstitial expression (P<0.025) in breast cancer. There was a negative correlation between expression (P<0.025), disease-free survival (P<0.025), and overall survival (P<0.05). It suggests that PCNA can reflect the proliferation status of cells, and its high expression can predict high recurrence rate and short survival time. Detection of PCNA may be helpful for adjuvant treatment of breast cancer.